VUČIĆ OBEZBEDIO TRIKAFTU

TL;DR

Serbia has secured the innovative drug "Trikafta" for patients with cystic fibrosis through an initiative by President Aleksandar Vučić.
Approximately 400 patients in Serbia suffer from cystic fibrosis, a rare genetic disease.
The drug "Trikafta" significantly improves the quality of life and offers a chance for a longer future for patients.
Cystic fibrosis causes dense mucus secretion that damages lungs and digestive organs.
Before 2012, rare diseases were not a focus in Serbia, and the average life expectancy for cystic fibrosis patients was around 25 years.
Since 2012, Serbia has been treating over 42 different rare diseases, including cystic fibrosis.
The country also implements screening programs for rare diseases, including cystic fibrosis, at birth.
Serbia provides three modern therapies for spinal muscular atrophy, similar to "Trikafta" in improving patient lives.
The availability of these treatments is facilitated by the Republican Health Insurance Fund.
The establishment of the Office for Rare Diseases, also initiated by President Vučić, provides support to patients and families facing rare illnesses.
The drug "Trikafta" became available in Serbia in December 2021, with patients reporting profound positive impacts on their lives and ability to plan for the future, including motherhood.

Continuer la lecture de l'article original